Abstract 437P
Background
Sarcopenia, characterized by a decline of skeletal muscle plus low muscle strength and/or physical performance, has emerged to be an important prognostic factor for advanced cancer patients. Sarcopenia is diagnosed if there is decreased muscle mass and either decreased muscle function or physical activity. The diagnostic tools for evaluating muscle mass in cancer patients was using muscle index derived from abdominal CT scan. However, the practicability of using CT scan for screening decreased muscle mass has been questioned. Until know there is limited data diagnostic value of Bio-impedance analysis (BIA) in cancer patients. The aim of this study is to know the correlation between BIA and abdominal CT scan to diagnose decreased muscle mass in cancer patients.
Methods
This cross-sectional study included adult cancer patients who underwent abdominal CT scans in purpose for diagnostic. BIA was performed in the same day when CT-scan was performed. CT-scans was analyzed using special software. BIA was performed using standing-posture 2-electrode BIA device BC-418 (BIA, Tanita Corp, Tokyo, Japan). Height adjusted appendicular skeletal muscle mass (ASM) was calculated from BIA. Height adjusted skeletal muscle Index (SMI) was performed from a single cross-sectional CT image (slice) at third lumbar (L3) for abdominal skeletal muscle area. We calculated Pearson’s r correlation coefficient between two parameters.
Results
A total of 39 patients were included. Twenty-eight (71.8%) patients were female. The mean of age was 51.18 +13.83 years old. Several type of cancer such as breast, lung, gastrointestinal and genitourinary cancer were included. Eleven (28.2%) patients were in advanced stage. Mean of height adjusted BIA was 6.60 + 0.98 kg/m2. Mean of height adjusted muscle mass was 42.25 + 7.57 cm2/m2. BIA and CT-derived muscle were moderately correlated (r = 0.72, p < 0.001).
Conclusions
This study showed that BIA- and CT-derived muscle mass was moderately correlated in adult cancer patients. Further research is needed to confirm this result.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract